{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-036399","form_type":"8-K","ticker":"ADMA","cik":"0001368514","company_name":"ADMA BIOLOGICS, INC.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.801898+00:00","generated_at":"2026-05-31T10:45:20.118214+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"ADMA Biologics Q2 revenue $107.2M (+78% YoY); raises FY2024 revenue guidance to >$400M","bullets":["Q2 2024 total revenue $107.2M, up 78% YoY; GAAP net income $32.1M vs loss of $6.4M a year ago.","Adjusted EBITDA $44.5M, up ~592% YoY; gross margin improved to 53.6% from 27.8%.","FY2024 revenue guidance raised to >$400M (from >$355M); FY2025 revenue >$445M (from >$410M).","FY2024 GAAP net income guidance raised to >$105M; adjusted EBITDA guidance >$150M.","Commercial-scale yield enhancement of ~20% from same starting plasma; potential benefit as early as Q4 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-036399","json":"https://secwatch.observer/filing/0001140361-24-036399.json","markdown":"https://secwatch.observer/filing/0001140361-24-036399.md","text":"https://secwatch.observer/filing/0001140361-24-036399.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1368514/000114036124036399/0001140361-24-036399-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1368514/000114036124036399/ef20033774_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:45:20.118214+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}